» Articles » PMID: 32935143

Impact of Protein Glycosylation on the Design of Viral Vaccines

Overview
Date 2020 Sep 16
PMID 32935143
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Glycans play crucial roles in various biological processes such as cell proliferation, cell-cell interactions, and immune responses. Since viruses co-opt cellular biosynthetic pathways, viral glycosylation mainly depends on the host cell glycosylation machinery. Consequently, several viruses exploit the cellular glycosylation pathway to their advantage. It was shown that viral glycosylation is strongly dependent on the host system selected for virus propagation and/or protein expression. Therefore, the use of different expression systems results in various glycoforms of viral glycoproteins that may differ in functional properties. These differences clearly illustrate that the choice of the expression system can be important, as the resulting glycosylation may influence immunological properties. In this review, we will first detail protein N- and O-glycosylation pathways and the resulting glycosylation patterns; we will then discuss different aspects of viral glycosylation in pathogenesis and in vaccine development; and finally, we will elaborate on how to harness viral glycosylation in order to optimize the design of viral vaccines. To this end, we will highlight specific examples to demonstrate how glycoengineering approaches and exploitation of different expression systems could pave the way towards better self-adjuvanted glycan-based viral vaccines.

Citing Articles

Expanding horizons of iminosugars as broad-spectrum anti-virals: mechanism, efficacy and novel developments.

Liu Q, Liu Y, Liu T, Fan J, Xia Z, Zhou Y Nat Prod Bioprospect. 2024; 14(1):55.

PMID: 39325109 PMC: 11427655. DOI: 10.1007/s13659-024-00477-5.


Cell-free -glycosylation of peptides using synthetic lipid-linked hybrid and complex -glycans.

Wenzel L, Hoffmann M, Rapp E, Rexer T, Reichl U Front Mol Biosci. 2023; 10:1266431.

PMID: 37767159 PMC: 10520871. DOI: 10.3389/fmolb.2023.1266431.


Deletion of the first glycosylation site promotes Lassa virus glycoprotein-mediated membrane fusion.

Dong S, Mao W, Liu Y, Jia X, Zhang Y, Zhou M Virol Sin. 2023; 38(3):380-386.

PMID: 37059226 PMC: 10311258. DOI: 10.1016/j.virs.2023.04.003.


Genomic reconstruction and features of glycosylation pathways in the apicomplexan parasites.

Wang D, Wang C, Zhu G Front Mol Biosci. 2022; 9:1051072.

PMID: 36465557 PMC: 9713705. DOI: 10.3389/fmolb.2022.1051072.


In silico design of refined ferritin-SARS-CoV-2 glyco-RBD nanoparticle vaccine.

Masoomi Nomandan S, Azimzadeh Irani M, Hosseini S Front Mol Biosci. 2022; 9:976490.

PMID: 36148012 PMC: 9486171. DOI: 10.3389/fmolb.2022.976490.


References
1.
Johannssen T, Lepenies B . Glycan-Based Cell Targeting To Modulate Immune Responses. Trends Biotechnol. 2017; 35(4):334-346. DOI: 10.1016/j.tibtech.2016.10.002. View

2.
Dwek R . Glycobiology: Toward Understanding the Function of Sugars. Chem Rev. 1996; 96(2):683-720. DOI: 10.1021/cr940283b. View

3.
Bagdonaite I, Wandall H . Global aspects of viral glycosylation. Glycobiology. 2018; 28(7):443-467. PMC: 7108637. DOI: 10.1093/glycob/cwy021. View

4.
Bagdonaite I, Vakhrushev S, Joshi H, Wandall H . Viral glycoproteomes: technologies for characterization and outlook for vaccine design. FEBS Lett. 2018; 592(23):3898-3920. DOI: 10.1002/1873-3468.13177. View

5.
Crispin M, Doores K . Targeting host-derived glycans on enveloped viruses for antibody-based vaccine design. Curr Opin Virol. 2015; 11:63-9. PMC: 4827424. DOI: 10.1016/j.coviro.2015.02.002. View